StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

Shares of OGEN opened at $0.30 on Friday. The stock has a market capitalization of $3.64 million, a price-to-earnings ratio of -0.04 and a beta of 0.38. Oragenics has a 1 year low of $0.25 and a 1 year high of $3.89. The business’s 50 day simple moving average is $0.33 and its 200-day simple moving average is $0.49.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.